<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: rely on third parties", fill: "#01796f"},
{source: "1: rely on third parties", target: "1: transaction processing system", fill: "#01796f"},
{source: "1: transaction processing system", target: "1: disruption", fill: "#01796f"},
{source: "1: disruption", target: "1: services could", fill: "#01796f"},
{source: "1: services could", target: "1: materially disrupt", fill: "#01796f"},
{source: "1: materially disrupt", target: "1: operations", fill: "#01796f"},
{source: "1: rely on third parties", target: "2: operations utilize", fill: "#ec3b83"},
{source: "2: operations utilize", target: "2: retail pharmacies", fill: "#ec3b83"},
{source: "2: retail pharmacies", target: "2: process thirdparty", fill: "#ec3b83"},
{source: "2: operations utilize", target: "5: interruption", fill: "#0093af"},
{source: "5: interruption", target: "5: service either through", fill: "#0093af"},
{source: "5: service either through", target: "5: systems availability", fill: "#0093af"},
{source: "5: systems availability", target: "5: telecommunications disruptions", fill: "#0093af"},
{source: "5: telecommunications disruptions", target: "5: significantly", fill: "#0093af"},
{source: "5: interruption", target: "12: We and other PBM ", fill: "#cd9575"},
{source: "12: We and other PBM ", target: "12: companies compete primarily on", fill: "#cd9575"},
{source: "12: companies compete primarily on", target: "12: price service", fill: "#cd9575"},
{source: "12: price service", target: "12: capabilities", fill: "#cd9575"},
{source: "12: capabilities", target: "12: clinical services", fill: "#cd9575"},
{source: "12: We and other PBM ", target: "13: competitive", fill: "#3c341f"},
{source: "13: competitive", target: "13: dominated by", fill: "#3c341f"},
{source: "13: dominated by", target: "13: significantly greater financial", fill: "#3c341f"},
{source: "13: significantly greater financial", target: "13: marketing resources purchasing power", fill: "#3c341f"},
{source: "13: marketing resources purchasing power", target: "13: competitive advantages", fill: "#3c341f"},
{source: "13: competitive", target: "35: initiatives", fill: "#e34234"},
{source: "35: initiatives", target: "35: complexity", fill: "#e34234"},
{source: "35: complexity", target: "35: requirements", fill: "#e34234"},
{source: "35: requirements", target: "35: expectations", fill: "#e34234"},
{source: "35: expectations", target: "35: effective", fill: "#e34234"},
{source: "35: effective", target: "35: program implementation", fill: "#e34234"},
{source: "35: program implementation", target: "35: government alters", fill: "#e34234"},
{source: "35: government alters", target: "35: territories", fill: "#e34234"},
{source: "35: territories", target: "35: participants", fill: "#e34234"},
{source: "35: participants", target: "35: employer groups", fill: "#e34234"},
{source: "35: employer groups", target: "35: winning contract renewals", fill: "#e34234"},
{source: "35: winning contract renewals", target: "35: new contracts under", fill: "#e34234"},
{source: "35: new contracts under", target: "35: competitive", fill: "#e34234"},
{source: "35: initiatives", target: "37: key clients", fill: "#0072bb"},
{source: "37: key clients", target: "37: significant", fill: "#0072bb"},
{source: "37: key clients", target: "38: key clients as", fill: "#efdecd"},
{source: "38: key clients as", target: "38: competitive", fill: "#efdecd"},
{source: "38: competitive", target: "38: consolidation", fill: "#efdecd"},
{source: "38: consolidation", target: "38: otherwise could", fill: "#efdecd"},
{source: "38: otherwise could", target: "38: adversely affect", fill: "#efdecd"},
{source: "38: adversely affect", target: "38: profitability", fill: "#efdecd"},
{source: "38: profitability", target: "38: growth prospects", fill: "#efdecd"},
{source: "38: key clients as", target: "44: could lose clients", fill: "#826644"},
{source: "44: could lose clients", target: "44: agreements with us", fill: "#826644"},
{source: "44: agreements with us", target: "44: competitive bid at", fill: "#826644"},
{source: "44: competitive bid at", target: "44: contract renewal", fill: "#826644"},
{source: "44: contract renewal", target: "44: financial condition", fill: "#826644"},
{source: "44: financial condition", target: "44: deteriorates", fill: "#826644"},
{source: "44: deteriorates", target: "44: companies with which", fill: "#826644"},
{source: "44: could lose clients", target: "98: prescription", fill: "#de6fa1"},
{source: "98: prescription", target: "98: profitability", fill: "#de6fa1"},
{source: "98: prescription", target: "START_HERE", fill: "#de6fa1"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmacy_benefit_management">Pharmacy benefit management</a></td>
      <td>In the United States, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans. According to the American Pharmacists Association, "PBMs are primarily responsible for developing and maintaining the formulary, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers, and processing and paying prescription drug claims." PBMs operate inside of integrated healthcare systems (e.g., Kaiser Permanente or Veterans Health Administration), as part of retail pharmacies (e.g., CVS Pharmacy or Rite-Aid), and as part of insurance companies (e.g., UnitedHealth Group).As of 2016, PBMs managed pharmacy benefits for 266 million Americans.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Mother">Significant Mother</a></td>
      <td>Significant Mother is an American television sitcom created by Erin Cardillo and Richard Keith. Starring Josh Zuckerman, Nathaniel Buzolic and Krista Allen, it premiered on The CW network on August 3 and ended its run on October 5, 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_advantage">Competitive advantage</a></td>
      <td>In business, a competitive advantage is the attribute that allows an organization to outperform its competitors.\nA competitive advantage may include access to natural resources, such as high-grade ores or a low-cost power source, highly skilled labor, geographic location, high entry barriers, and access to new technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitive_programming">Competitive programming</a></td>
      <td>Competitive programming is a mind sport usually held over the Internet or a local network, involving participants trying to program according to provided specifications. Contestants are referred to as sport programmers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition_(economics)">Competition (economics)</a></td>
      <td>In economics, competition is a scenario where different economic firms are in contention to obtain goods that are limited by varying the elements of the marketing mix: price, product, promotion and place. In classical economic thought, competition causes commercial firms to develop new products, services and technologies, which would give consumers greater selection and better products.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Porter's_five_forces_analysis">Porter's five forces analysis</a></td>
      <td>Porter's Five Forces Framework is a method of analysing the operating environment of a competition of a business. It draws from industrial organization (IO) economics to derive five forces that determine the competitive intensity and, therefore, the attractiveness (or lack thereof) of an industry in terms of its profitability.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_participant">Market participant</a></td>
      <td>The term market participant is another term for economic agent, an actor and more specifically a decision maker in a model of some aspect of the economy. For example, buyers and sellers are two common types of agents in partial equilibrium models of a single market.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_participants_in_the_coronation_procession_of_Elizabeth_II">List of participants in the coronation procession of Elizabeth II</a></td>
      <td>The procession for the coronation of Elizabeth II was an element of the ceremony in which court, clerical, governmental, and parliamentary officials from around the Commonwealth of Nations moved in a set order of precedence through the streets of London, England, and into Westminster Abbey, where the coronation took place.\n\n\n== Chaplains ==\n\n\n== Officers of the Orders of Knighthood ==\n\n\n== Standards ==\n\n\n== Members of the Royal Household ==\n\n\n== Prime Ministers of the Commonwealth of Nations ==\n\n\n== Archbishops and the Lord Chancellor ==\n\n\n== Duke of Edinburgh ==\n\n\n== Bearer of the Regalia ==\n\n\n== The Queen ==\n\n\n== References ==\nThe London Gazette, no.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Participant_observation">Participant observation</a></td>
      <td>Participant observation is one type of data collection method by practitioner-scholars typically used in qualitative research and ethnography. This type of methodology is employed in many disciplines, particularly anthropology (incl.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Participant_(company)">Participant (company)</a></td>
      <td>Participant is a Los Angeles, California-based film production company founded in 2004 by Jeffrey Skoll, dedicated to entertainment intended to spur social change. The company finances and co-produces film and television content, as well as digital entertainment through its subsidiary SoulPancake, which the company acquired in 2016.The company was originally named Participant Productions and went on to become a well-known independent financier.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Custodial_participant">Custodial participant</a></td>
      <td>A custodial participant is a person who confirms a stock exchange trade on behalf of his client.\n\n\n== Explanation ==\nWhen a client enters buy/sell order for trading on a stock exchange, the trading member or stockbroker receives his order and inserts it into the Stock Exchange Trading System.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_analysis">Profitability analysis</a></td>
      <td>In cost accounting, profitability analysis is an analysis of the profitability of an organisation's output. Output of an organisation can be grouped into products, customers, locations, channels and/or transactions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_Profitability_Analysis">Customer Profitability Analysis</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Small_Is_Profitable">Small Is Profitable</a></td>
      <td>Small Is Profitable: The Hidden Economic Benefits of Making Electrical Resources the Right Size is a 2002 book by energy analyst Amory Lovins and others.  The book describes 207 ways in which the size of "electrical resources"—devices that make, save, or store electricity—affects their economic value.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer Profitability Analysis (in short CPA) is a management accounting and a credit underwriting method, allowing businesses and lenders to determine the profitability of each customer or segments of customers, by attributing profits and costs to each customer separately. CPA can be applied at the individual customer level (more time consuming, but providing a better understanding of business situation) or at the level of customer aggregates / groups (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Net_income">Net income</a></td>
      <td>In business and accounting, net income (also total comprehensive income, net earnings, net profit, bottom line, sales profit, or credit sales) is an entity's income minus cost of goods sold, expenses, depreciation and amortization, interest, and taxes for an accounting period.It is computed as the residual of all revenues and gains less all expenses and losses for the period, and has also been defined as the net increase in shareholders' equity that results from a company's operations. It is different from gross income, which only deducts the cost of goods sold from revenue.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prescription_charges">Prescription charges</a></td>
      <td>Charges for prescriptions for medicines and some medical appliances are payable by adults in England under the age of 60, although a majority are exempt for various reasons. Charges were abolished in NHS Wales in 2007, Health and Social Care in Northern Ireland in 2010 and by NHS Scotland in 2011.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NATIONAL MEDICAL HEALTH CARD SYSTEMS INC      Item 1A Risk Factors Affecting Our Business        We  <font color="blue">rely on third parties</font> for our point of sale information system and     <font color="blue">transaction processing system</font>, and any <font color="blue">disruption</font> in these <font color="blue">services could</font>     <font color="blue">materially disrupt</font> our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> utilize an electronic network connecting <font color="blue">approximately</font> 55cmam000     <font color="blue">retail pharmacies</font> to process third-party claims</td>
    </tr>
    <tr>
      <td>This system is <font color="blue">provided by</font>     a third-party adjudication vendor</td>
    </tr>
    <tr>
      <td>Because claims are <font color="blue">adjudicated</font> in real     time, <font color="blue">systems availability</font> and <font color="blue">re<font color="blue">liability</font></font> are key to <font color="blue">meeting customers</font>’     <font color="blue">service <font color="blue">expectations</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> in real time service, either through     <font color="blue">systems availability</font> or tele<font color="blue">communications</font> <font color="blue">disruption</font>s can <font color="blue"><font color="blue">significant</font>ly</font>     damage the quality of service we provide</td>
    </tr>
    <tr>
      <td>Our PBM <font color="blue">services also <font color="blue">depend on</font></font>     third-party  <font color="blue">proprietary</font>  software  to  perform  <font color="blue">automated transaction</font>     processing</td>
    </tr>
    <tr>
      <td>There can be no assurance that our business and results of     <font color="blue">operations</font>  will  not be materially harmed by service <font color="blue">interruption</font>s or     <font color="blue">software performance problems</font></td>
    </tr>
    <tr>
      <td>We  are  in the process of <font color="blue">transitioning</font> to <font color="blue">new software</font> <font color="blue">provided by</font> a     third-party adjudication vendor and any severe <font color="blue">interruption</font> during the     transition could <font color="blue">materially disrupt</font> our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>All <font color="blue"><font color="blue">new clients</font> joining us will utilize</font> our <font color="blue">new software</font>, and we intend to     <font color="blue">migrate <font color="blue">existing clients</font></font> to this <font color="blue">new software</font></td>
    </tr>
    <tr>
      <td>It is possible that we may     experience service <font color="blue">interruption</font>s in <font color="blue">connection with</font> the <font color="blue">introduction</font> of the     <font color="blue">new software</font>, which may cause <font color="blue">affected clients</font> to <font color="blue">become dissatisfied with</font>     us and <font color="blue">seek services elsewhere</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face intense competition</font> in the <font color="blue">pharmacy benefit <font color="blue">management</font> industry</font></td>
    </tr>
    <tr>
      <td><font color="blue">We and other PBM </font><font color="blue">companies compete primarily on</font> the basis of price, service,     reporting <font color="blue">capabilities</font> and <font color="blue">clinical services</font></td>
    </tr>
    <tr>
      <td>The PBM industry is very     <font color="blue">competitive</font> and <font color="blue">dominated by</font>, in most cases, a few large, profitable and     well-established  companies  with  <font color="blue"><font color="blue">significant</font>ly</font> greater financial and     marketing resources, purchasing power and other <font color="blue">competitive</font> advantages</td>
    </tr>
    <tr>
      <td>Based  on  published  reports, a limited number of <font color="blue">national companies</font>,     including PBM <font color="blue">companies such as</font> Medco Health Solutions Inc, Express Scripts     Inc</td>
    </tr>
    <tr>
      <td>and Caremark Rx, Inc</td>
    </tr>
    <tr>
      <td>have an <font color="blue">aggregate market</font> share of <font color="blue">approximately</font>     70prca of <font color="blue"><font color="blue">prescription</font> volume</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitors</font> also</font> include <font color="blue">drug retailers</font>,     <font color="blue">physician practice <font color="blue">management</font> companies</font>, and insurance companies/health     <font color="blue">maintenance organizations</font></td>
    </tr>
    <tr>
      <td>We may also experience <font color="blue">competition from new</font>     <font color="blue">competitors</font>  in  the future</td>
    </tr>
    <tr>
      <td>If we do not <font color="blue">compete <font color="blue">effective</font>ly with</font> our     <font color="blue">competitors</font>, our business and results of <font color="blue">operations</font> may suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainty </font>regarding the <font color="blue">implementation</font> and impact of <font color="blue">Medicare Part D </font>may     <font color="blue"><font color="blue">adversely</font> impact</font> our business and financial results</td>
    </tr>
    <tr>
      <td>The MMA created a new, voluntary <font color="blue">prescription</font> <font color="blue">drug benefit</font> for <font color="blue">Medicare     </font><font color="blue">beneficiaries entitled</font> to Medicare <font color="blue">benefits under</font> Part A or enrolled in     <font color="blue">Medicare Part B </font><font color="blue">effective</font> January 1, 2006</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently <font color="blue">participate</font></font> in the     <font color="blue">administration</font> of the Medicare <font color="blue">drug benefit</font>: (i) through the provision of     PBM  services  to  our health plan clients and other clients that have     <font color="blue">qualified as</font> a PDP or a MA-PD, and (ii) by assisting employers, unions and     other  health  plan  clients that qualify for the <font color="blue">retiree drug subsidy</font>     <font color="blue">available under</font> <font color="blue">Medicare Part D </font><font color="blue">by collecting</font> and <font color="blue">submitting eligibility</font>     and/or drug cost data to CMS for them in order to obtain the subsidy</td>
    </tr>
    <tr>
      <td>Our     existing PBM business could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if our <font color="blue">clients decide</font> to     <font color="blue">discontinue</font>  providing  <font color="blue">prescription</font> <font color="blue">drug benefit</font>s altogether to their     Medicare-eligible members</td>
    </tr>
    <tr>
      <td>We are not yet able to assess the impact that     <font color="blue">Medicare Part D </font>will have on our clients’ decisions to continue to offer a     <font color="blue">prescription</font> <font color="blue">drug benefit</font> to their Medicare-eligible members</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________    [56]Table of Contents       In addition, as an approved PDP sponsor for 2007, we intend to commence     offering <font color="blue">Medicare Part D </font><font color="blue">pharmacy benefits</font> to <font color="blue"><font color="blue">employer groups</font> on</font> January 1,     2007, subject to <font color="blue">entering into</font> a <font color="blue">formal agreement with</font> CMS during the fourth     quarter of 2006</td>
    </tr>
    <tr>
      <td>This will be the first time we are a <font color="blue">direct contractor</font> to     the <font color="blue">federal <font color="blue">government</font></font> and subject to the rules, <font color="blue">regulations</font> and <font color="blue">enforcement</font>     authority of the <font color="blue">federal <font color="blue">government</font></font> over its <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>In addition, under     <font color="blue"><font color="blue">regulations</font> established by</font> CMS <font color="blue">governing participation</font> in the Medicare Part     D program, our subsidiary, NMHC Group Solutions, must be a risk-bearing     entity <font color="blue">regulated under</font> state <font color="blue">insurance laws</font> and must obtain licensure as a     <font color="blue">domestic insurance company prior</font> to <font color="blue">entering into</font> a formal contract with     CMS <font color="blue">NMHC Group Solutions </font>has <font color="blue">been approved</font> to operate as a risk-bearing     entity in its domicile state, Delaware, and has filed <font color="blue">applications</font> for     licensure in the 49 other states and Washington DC, and Puerto Rico</td>
    </tr>
    <tr>
      <td>We     are <font color="blue">at various stages with</font> these <font color="blue">applications</font> in the <font color="blue">ancillary</font> states as     some states are considering our application, others we have not heard back     from  and  others  have  been  withdrawn  for  failure to <font color="blue">meet certain</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We expect to operate under a <font color="blue">three year wavier granted by</font> CMS     for these other states and <font color="blue">territories</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">applications</font> are in various     stages, and we can <font color="blue">give no assurance</font> that they will be approved</td>
    </tr>
    <tr>
      <td>We have invested substantial amounts of time and resources to our <font color="blue">Medicare     </font><font color="blue">drug benefit</font> program which may impact our business and financial results</td>
    </tr>
    <tr>
      <td>We  have  currently  committed  over dlra6dtta3 million in a <font color="blue">cash account</font> in     <font color="blue">connection with</font> CMS <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>As we <font color="blue">become licensed as</font> a risk-bearing     entity in <font color="blue">additional</font> states, we expect to deposit an <font color="blue">additional</font> dlra8 million     in the near future to fulfill statutory <font color="blue">requirements</font> in various states</td>
    </tr>
    <tr>
      <td>The     deposited  cash  is  restricted  and will not be available to fund our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we may not be able to realize any return on our     investments in Medicare <font color="blue">initiatives</font> if the cost and <font color="blue">complexity</font> of recent     changes  by and <font color="blue">requirements</font> of CMS exceed our <font color="blue">expectations</font> or prevent     <font color="blue">effective</font>  program <font color="blue">implementation</font>; if the <font color="blue"><font color="blue">government</font> alters</font> or reduces     funding of Medicare programs because of the higher-than-anticipated cost to     taxpayers of the MMA or for other reasons; if we fail to become a risk     bearing entity prior to the expiration of the CMS waivers for the 49 other     states and <font color="blue">territories</font>; or if we fail to design and maintain programs that     are attractive to our clients or individual Medicare <font color="blue">participants</font>; or if we     are not successful in retaining <font color="blue">employer groups</font> and their enrollees, or     <font color="blue">winning <font color="blue">contract renewal</font>s</font> or <font color="blue">new contracts under</font> the MMA’s <font color="blue">competitive</font>     bidding  process</td>
    </tr>
    <tr>
      <td>There are many <font color="blue">uncertainties about</font> the financial and     <font color="blue"><font color="blue">regulatory</font> risks</font> of <font color="blue">participating</font> in the Medicare <font color="blue"><font color="blue">prescription</font> drug program</font>,     and we can <font color="blue">give no assurance</font> that these risks will not be material to our     business in <font color="blue">future periods</font></td>
    </tr>
    <tr>
      <td>We rely on a limited number of <font color="blue">key clients</font> for a <font color="blue">significant</font> portion of our     revenues</td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">key clients</font> as a result of <font color="blue">competitive</font>     bidding  for  contracts,  <font color="blue">consolidation</font> of clients or otherwise, could     <font color="blue"><font color="blue">adversely</font> affect</font> our business, <font color="blue">profitability</font> and <font color="blue">growth prospects</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> a limited number of clients for a <font color="blue">significant</font> portion of our     revenue</td>
    </tr>
    <tr>
      <td>Our top ten clients generated <font color="blue">approximately</font> 48prca, and our top twenty     clients generated <font color="blue">approximately</font> 60prca, of the claims we processed in 2006,     <font color="blue">although no single client accounted</font> for greater than 15prca of our revenues</td>
    </tr>
    <tr>
      <td>Our client MVP, <font color="blue">which consists</font> of <font color="blue">approximately</font> 15prca of our gross dollar     value of all <font color="blue"><font color="blue">prescription</font>s filled</font> for <font color="blue">fiscal year</font> ended June 30, 2006, will     not be renewing their <font color="blue"><font color="blue">contract with us</font> which will</font> expire on <font color="blue">December </font>31,     2006</td>
    </tr>
    <tr>
      <td>Many of our clients put their contracts out for <font color="blue">competitive</font> bidding prior to     expiration</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font>bidding requires costly and time-consuming efforts     on our behalf and, even after we have <font color="blue">won such <font color="blue">bidding processes</font></font>, we can     incur  <font color="blue">significant</font> expense in <font color="blue">proceedings</font> or <font color="blue"><font color="blue">litigation</font> contesting</font> the     adequacy or fairness of these <font color="blue">bidding processes</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could lose clients</font> if     they cancel their <font color="blue"><font color="blue">agreements</font> with us</font>, if we fail to win a <font color="blue">competitive</font> bid at     the time of <font color="blue">contract renewal</font>, if the <font color="blue">financial condition</font> of any of our     clients  <font color="blue">deteriorates</font>  or  if our clients are acquired by, or acquire,     <font color="blue">companies with which</font> we do not have contracts</td>
    </tr>
    <tr>
      <td>Over the past several years,     self-funded  employers,  TPAs  and  other  <font color="blue">managed care</font> companies have     experienced <font color="blue">significant</font> <font color="blue">consolidation</font></td>
    </tr>
    <tr>
      <td><font color="blue">Consolidations </font>by their very nature     reduce the number of clients who may need our services</td>
    </tr>
    <tr>
      <td>A client involved in     a merger or <font color="blue"><font color="blue">acquisition</font> by</font> a company that is not a client of ours may not     renew, and in some <font color="blue">instances may terminate</font> its <font color="blue">contract with us</font></td>
    </tr>
    <tr>
      <td>Our clients     have been, and <font color="blue">may continue</font> to be, subject to <font color="blue">consolidation</font> pressures</td>
    </tr>
    <tr>
      <td>Our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> could be <font color="blue">adversely</font>     affected if we were to lose one or more of our <font color="blue">significant</font> clients</td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________    [57]Table of Contents       We may be liable for damages and other expenses that are not <font color="blue">covered by</font> our     <font color="blue">insurance policies</font></td>
    </tr>
    <tr>
      <td>Various aspects of our business may subject us to <font color="blue">litigation</font> and <font color="blue">liability</font>     for damages, for example, the performance of PBM services and the operation     of our <font color="blue">mail service</font> and <font color="blue"><font color="blue">specialty service</font> pharmacies</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">successful product</font>     or <font color="blue">professional</font> <font color="blue">liability</font> claim in excess of our <font color="blue">insurance coverage</font> where we     are required to pay damages, incur legal costs or <font color="blue">face negative publicity</font>     could have a material adverse effect on our business, results of <font color="blue">operations</font>     and <font color="blue">financial condition</font>, our business reputation and our ability to attract     and retain clients, network pharmacies and employees</td>
    </tr>
    <tr>
      <td>While we intend to     maintain <font color="blue">professional</font> and general <font color="blue">liability</font> <font color="blue">insurance coverage</font> at all times,     we <font color="blue">cannot provide assurances</font> that we will be able to maintain insurance in     the future, that <font color="blue">insurance will</font> be <font color="blue">available on</font> acceptable terms or that     insurance  will  be  adequate to cover any or all <font color="blue">potential product</font> or     <font color="blue">professional</font> <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Specifically, due to the high cost of hurricane-related insurance premiums,     we may not always be <font color="blue">fully insured against</font> these risks, including hurricane     related risks in our <font color="blue">Mail Service </font><font color="blue"><font color="blue">facility</font> located</font> in Miramar, Florida</td>
    </tr>
    <tr>
      <td>While it is our goal to be <font color="blue">fully insured against</font> natural disasters at all     times, we <font color="blue">cannot provide assurances</font> that we will be able to obtain coverage     at favorable rates that outweigh the risks</td>
    </tr>
    <tr>
      <td>Demands by our clients for <font color="blue">enhanced service levels</font> or <font color="blue">possible loss</font> or     <font color="blue">unfavorable modification</font> of <font color="blue">contracts with</font> our <font color="blue">clients could <font color="blue">negatively</font></font>     affect our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As our <font color="blue">clients face</font> the <font color="blue">continued rapid growth</font> in <font color="blue"><font color="blue">prescription</font> drug costs</font>,     they may demand <font color="blue">additional</font> services and <font color="blue">enhanced service levels</font> to help     mitigate the increase in spending</td>
    </tr>
    <tr>
      <td>We operate in a very <font color="blue">competitive</font> PBM     <font color="blue">environment</font>, and as a result, we may not be able to increase our fees to     compensate for these <font color="blue">increased services which could <font color="blue">negatively</font> affect</font> our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Due to the term of our <font color="blue">contracts with</font> clients, if we are unable to extend     those contracts or replace any <font color="blue">lost clients</font>, our future business and results     of <font color="blue">operation would</font> be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently provide</font> PBM services to thousands of clients</td>
    </tr>
    <tr>
      <td>Our contracts     <font color="blue">with clients generally</font> do not have <font color="blue">terms longer than three years</font> and, in     some cases, are <font color="blue">terminable by</font> the <font color="blue">client on relatively</font> short notice</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">larger clients generally seek bids from</font> other PBM providers in advance of     the expiration of their contracts</td>
    </tr>
    <tr>
      <td>In addition, we believe the <font color="blue">managed care</font>     industry is undergoing substantial <font color="blue">consolidation</font>, and another party that is     not our <font color="blue">client could</font> acquire some of our <font color="blue">managed care</font> clients</td>
    </tr>
    <tr>
      <td>In such case,     the <font color="blue">likelihood such client would renew</font> its PBM <font color="blue">contract with us</font> could be     reduced</td>
    </tr>
    <tr>
      <td>If  several of these large <font color="blue">clients elect</font> not to extend their     <font color="blue">relationship with us</font>, and we are not successful in <font color="blue">generating sales</font> to     replace the lost business, our future business and results of <font color="blue">operations</font>     would be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> <font color="blue">could suffer</font> if we lose our <font color="blue">pharmacy network</font>     <font color="blue">affiliations</font> or if our <font color="blue">specialty pharmacy</font> is <font color="blue">excluded from <font color="blue">third party</font></font>     <font color="blue">pharmacy network</font>s</td>
    </tr>
    <tr>
      <td>Our PBM <font color="blue">operations</font> are <font color="blue">dependent</font> to a <font color="blue">significant</font> extent on our ability to     obtain <font color="blue">discounts</font> on <font color="blue">prescription</font> purchases from <font color="blue">retail pharmacies</font> that can     be <font color="blue">utilized by</font> our clients and their <font color="blue">participants</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">contracts with</font> retail     pharmacies, which are non-exclusive, are generally <font color="blue">terminable by</font> either     party on short notice</td>
    </tr>
    <tr>
      <td>If one or more of our top pharmacy chains elects to     terminate its <font color="blue">relationship with us</font> or if we are only able to continue our     <font color="blue">relationship on terms less</font> favorable to us, access to <font color="blue">retail pharmacies</font> by     our clients and their health plan <font color="blue">participants</font>, and our business, results of     <font color="blue">operations</font> and <font color="blue">financial condition</font> <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>In addition, some large     <font color="blue">retail pharmacy chains either</font> own or have <font color="blue">strategic <font color="blue">alliances with</font></font> PBMs or     could attempt to acquire or enter into these kinds of <font color="blue">relationships</font> in the     future</td>
    </tr>
    <tr>
      <td><font color="blue">Ownership </font>of, or <font color="blue">alliances with</font>, PBMs <font color="blue">by retail pharmacy chains</font>,     <font color="blue">particularly</font> large <font color="blue">pharmacy chains which control</font> a <font color="blue">significant</font> amount of     retail  pharmacy  business, could have material <font color="blue">adverse effects on</font> our     <font color="blue">relationships</font> with those retail pharmacy chains, <font color="blue">particularly</font> the <font color="blue">discounts</font>     they  are  willing  to make available, and on our business, results of     <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>31     ______________________________________________________________________    [58]Table of Contents       Specialty Service <font color="blue">contracts with</font> <font color="blue">third party</font> payors, including other PBMs,     state Medicaid, Medicare, and insurance companies, to become <font color="blue">participants</font> in     their networks</td>
    </tr>
    <tr>
      <td>We derive 52prca of <font color="blue">specialty revenues from</font> other <font color="blue">third party</font>     payors</td>
    </tr>
    <tr>
      <td>If the <font color="blue">third party</font> payor determines to carve out exclusive specialty     <font color="blue">agreements</font> to a <font color="blue">specific specialty vendor</font>, we <font color="blue">would no longer</font> have access to     the revenues generated through such relationship with such <font color="blue">third party</font>     payor</td>
    </tr>
    <tr>
      <td>We may be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by the loss of our <font color="blue">relationships</font> with one or     more <font color="blue"><font color="blue">key <font color="blue">pharmaceutical</font></font> <font color="blue">manufacturers</font></font> or if <font color="blue">rebate payments</font> we receive from     <font color="blue"><font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> decline</font></td>
    </tr>
    <tr>
      <td>We receive rebates from numerous <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> <font color="blue">based on</font> the     use of selected brand <font color="blue">name drugs</font> by <font color="blue">participants</font> of health plans sponsored     by our clients, as well as fees for other programs and services</td>
    </tr>
    <tr>
      <td>We believe     our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font> may be <font color="blue">adversely</font>     affected if:           •   we lose <font color="blue">relationships</font> with one or more <font color="blue">key <font color="blue">pharmaceutical</font></font>     <font color="blue">manufacturers</font>;           •   <font color="blue">rebates decline due</font> to the failure of our health plan clients to meet     market share or other thresholds;           •   <font color="blue">legal restrictions</font> are <font color="blue">imposed on</font> the ability of <font color="blue">pharmaceutical</font>     <font color="blue">manufacturers</font> to <font color="blue">offer rebates</font> or purchase our programs or services; or           •   <font color="blue">pharmaceutical</font> <font color="blue">manufacturers</font> choose not to <font color="blue">offer rebates</font> or purchase     our programs or services</td>
    </tr>
    <tr>
      <td>Over the next few years, as patents expire covering many brand <font color="blue">name drugs</font>     that currently have substantial market share, generic <font color="blue">products will</font> be     introduced that may <font color="blue">substantially</font> reduce the market share of these brand     <font color="blue">name drugs</font></td>
    </tr>
    <tr>
      <td>Historically, <font color="blue">manufacturers</font> of <font color="blue">generic drugs</font> have not offered     <font color="blue">formulary rebates on</font> their drugs</td>
    </tr>
    <tr>
      <td>Our <font color="blue">profitability</font> could be <font color="blue">adversely</font>     affected  if  the  use  of  newly  approved, brand <font color="blue">name drugs</font> added to     <font color="blue">formularies</font>, does not offset any decline in use of brand <font color="blue">name drugs</font> whose     patents expire or if rebates are not <font color="blue">offered by</font> the <font color="blue">manufacturers</font> of such     <font color="blue">newly approved</font> brand <font color="blue">name drugs</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">effective</font>ly manage our growth</td>
    </tr>
    <tr>
      <td>Our growth in <font color="blue">operations</font> has placed <font color="blue">significant</font> demands on our <font color="blue">management</font>     and other resources, which is likely to continue</td>
    </tr>
    <tr>
      <td>Our business has grown     rapidly since 2000, in part due to <font color="blue"><font color="blue">acquisition</font>s</font>, with total annual revenue     increasing from dlra167dtta7 million during fiscal 2000 to dlra862dtta9 million during     fiscal 2006</td>
    </tr>
    <tr>
      <td>Our business strategy is to continue to seek to expand our     <font color="blue">operations</font> through strategic <font color="blue"><font color="blue">acquisition</font>s</font> and <font color="blue">organic growth through</font> the     <font color="blue">increased marketing</font> of our services and by expanding the range of services     we offer</td>
    </tr>
    <tr>
      <td>We have acquired <font color="blue">seven companies</font> in the <font color="blue">last six years</font></td>
    </tr>
    <tr>
      <td>If we are     unable to finance our <font color="blue">continued growth</font> or manage our <font color="blue">future expansion</font>, our     business and results of <font color="blue">operations</font> could be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends on</font> our ability to retain our senior <font color="blue">management</font> and key     personnel</td>
    </tr>
    <tr>
      <td>We  depend to a <font color="blue">significant</font> extent on certain key personnel and senior     <font color="blue">management</font>, in particular those that have long-standing <font color="blue">relationships</font> within     the PBM industry, which help us to obtain <font color="blue">new clients</font></td>
    </tr>
    <tr>
      <td>Accordingly, it is     important for us to retain our existing <font color="blue">management</font> and to attract, hire and     retain  <font color="blue">additional</font> highly skilled and motivated officers, managers and     employees</td>
    </tr>
    <tr>
      <td>Therefore, losing the services of one or more members of our     senior <font color="blue">management</font> or our key employees could <font color="blue"><font color="blue">adversely</font> affect</font> our business     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>32     ______________________________________________________________________    [59]Table of Contents       Our <font color="blue">success depends on</font> our ability to <font color="blue">manage <font color="blue">potential problems</font></font> and risks     related to <font color="blue">future <font color="blue"><font color="blue">acquisition</font>s</font></font></td>
    </tr>
    <tr>
      <td>Part  of  our  growth strategy includes making <font color="blue"><font color="blue">acquisition</font>s</font>, including     <font color="blue">specialty pharmacy</font> <font color="blue">businesses</font> <font color="blue">and PBM </font><font color="blue">businesses</font> meeting specific criteria</td>
    </tr>
    <tr>
      <td>Our ability to continue to expand successfully through <font color="blue"><font color="blue">acquisition</font>s</font> depends     on many factors, including our ability to identify <font color="blue"><font color="blue">acquisition</font> prospects</font> and     negotiate and close <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>Even if we complete <font color="blue">future <font color="blue"><font color="blue">acquisition</font>s</font></font>:           •   we could fail to <font color="blue">successfully integrate</font> the <font color="blue">operations</font>, services and     products of an acquired company;           •   <font color="blue">there could</font> be <font color="blue">inconsistencies</font> in standards, controls, procedures and     <font color="blue">policies among</font> the companies being combined or <font color="blue">assimilated which would</font> make     it more <font color="blue">difficult</font> to implement and harmonize company-wide financial,     accounting, billing, information <font color="blue">technology</font> and other systems;           •   we may experience <font color="blue">difficult</font>ies maintaining the quality of products and     services that acquired companies have <font color="blue">historically provided</font>;           •   we would be required to amortize the <font color="blue">identifiable intangible assets</font> of     an acquired business, <font color="blue">which will reduce</font> our net income in the years     following its <font color="blue">acquisition</font>, and we also would be required to reduce our net     income in <font color="blue">future years</font> if we were to experience an <font color="blue">impairment</font> of goodwill or     other <font color="blue">intangible assets attributable</font> to an <font color="blue">acquisition</font>;           •   we could be exposed to <font color="blue">unanticipated liabilities</font> of acquired     <font color="blue">businesses</font>;           •   our <font color="blue">management</font>’s attention could be <font color="blue">diverted from</font> other business     concerns; and           •   we <font color="blue">could lose key employees</font> or customers of the acquired business</td>
    </tr>
    <tr>
      <td>There are <font color="blue">risks associated with integrating</font> and operating newly acquired     <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>We can <font color="blue">give no assurance</font> that we <font color="blue">will successfully</font> operate any     new business we acquire in the future</td>
    </tr>
    <tr>
      <td>If we are unable to overcome the     <font color="blue">potential problems</font> and <font color="blue">inherent risks</font> related to our recent and future     <font color="blue"><font color="blue">acquisition</font>s</font>, our business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font>     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Failure of our health plan clients to pay for <font color="blue">prescription</font> claims or a delay     in payment of those claims could have a material adverse effect on our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our  contracts  with <font color="blue">retail pharmacies</font> that <font color="blue">participate</font> in our network     <font color="blue">generally obligate us</font> to make payments for <font color="blue">prescription</font> claims even if we     are not <font color="blue">reimbursed by</font> our clients</td>
    </tr>
    <tr>
      <td>If our <font color="blue">clients delay</font> their <font color="blue">reimbursement</font>     payments or fail to make payments for <font color="blue">prescription</font> claims, it could have a     material adverse effect on our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">could suffer</font> civil and/or <font color="blue">criminal penalties</font>, lose clients, be required     to pay substantial damages or make <font color="blue">significant</font> changes to our <font color="blue">operations</font> if     we fail to <font color="blue"><font color="blue">comply with</font> complex</font> and <font color="blue">rapidly evolving laws</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>During  the past several years, the US <font color="blue"><font color="blue">health care</font> industry</font> has been     subject to an increase in <font color="blue"><font color="blue">government</font>al regulation at both</font> the federal and     state levels</td>
    </tr>
    <tr>
      <td>Numerous state and <font color="blue">federal laws</font> and <font color="blue">regulations</font> affect our     business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">categories</font> include, but are not <font color="blue">necessarily</font>     limited to:           •   <font color="blue">health care</font> fraud and <font color="blue">abuse laws</font> and <font color="blue">regulations</font>, which prohibit     <font color="blue">certain types</font> of payments and <font color="blue">referrals as well as false</font> claims made in     <font color="blue">connection with</font> health benefit programs;           •   privacy and <font color="blue">confidentiality laws</font> and <font color="blue">regulations</font>, including those     under HIPAA;           •   ERISA and related <font color="blue">regulations</font>, which regulate many <font color="blue">health care</font> plans;           •   potential regulation <font color="blue">of the PBM </font><font color="blue">industry by</font> the US Food and Drug     Administration;           •   the Medicare <font color="blue">prescription</font> drug coverage law and CMS <font color="blue">regulations</font>;           •   <font color="blue">consumer protection</font> and <font color="blue">unfair trade practice laws</font> and <font color="blue">regulations</font>;           •   various licensure laws, such as state insurance, <font color="blue">managed care</font> and     <font color="blue">third party</font> administrator licensure laws;           •   <font color="blue">pharmacy laws</font> and <font color="blue">regulations</font>;           •   <font color="blue">antitrust lawsuits challenging</font> PBM <font color="blue">pricing practices</font>;           •   state <font color="blue"><font color="blue">legislation</font> regulating</font> PBMs or imposing <font color="blue">fiduciary</font> status on     PBMs;                                           33     ______________________________________________________________________    [60]Table of Contents         •   <font color="blue">drug pricing <font color="blue">legislation</font></font>, including “most favored nation” pricing and     “unitary pricing” <font color="blue">legislation</font>;           •   other <font color="blue">Medicare and Medicaid </font><font color="blue">reimbursement</font> <font color="blue">regulations</font>;           •   <font color="blue">pending <font color="blue">legislation</font></font> regarding <font color="blue">importation</font> of <font color="blue">drug products into</font> the     United States;           •   <font color="blue"><font color="blue">legislation</font> imposing benefit</font> plan design restrictions, which limit how     our clients can design their <font color="blue">drug benefit</font> plans;           •   <font color="blue">network pharmacy access laws</font>, including “any <font color="blue">willing provider</font>” and     “due process” <font color="blue">legislation</font>, that <font color="blue">affect aspects</font> of our <font color="blue">pharmacy network</font>     contracts; and           •   <font color="blue">formulary development</font> and <font color="blue">disclosure laws</font></td>
    </tr>
    <tr>
      <td>These  and other <font color="blue"><font color="blue">regulatory</font> matters</font> are discussed in more detail under     “Business - Government Regulation” below</td>
    </tr>
    <tr>
      <td>If  we  fail  to  comply  with  existing or <font color="blue">future applicable laws</font> and     <font color="blue">regulations</font>,  we  could  <font color="blue">suffer civil</font> or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>We devote     <font color="blue">significant</font> operational and <font color="blue">managerial resources</font> to <font color="blue">comply with</font> these laws     and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Although we believe that we are operating our business in     substantial <font color="blue">compliance with</font> all existing legal <font color="blue">requirements</font> material to our     business, <font color="blue">different interpretations</font> and <font color="blue">enforcement</font> policies of these laws     and  <font color="blue">regulations</font> could subject our <font color="blue">current practices</font> to <font color="blue">allegations</font> of     <font color="blue">impropriety</font> or <font color="blue">illegality</font>, or could require us to make <font color="blue">significant</font> changes     to our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">cannot predict</font> the impact of future     <font color="blue">legislation</font> and <font color="blue">regulatory</font> changes on our business or assure you that we     will be able to obtain or maintain the <font color="blue">regulatory</font> approvals required to     operate our business</td>
    </tr>
    <tr>
      <td><font color="blue">Government  </font>efforts  to <font color="blue">reduce <font color="blue">health care</font> costs</font> and <font color="blue">alter <font color="blue">health care</font></font>     <font color="blue">financing practices could lead</font> to a <font color="blue">decreased demand</font> for our services or to     reduced rebates from <font color="blue">manufacturers</font></td>
    </tr>
    <tr>
      <td>Efforts to control <font color="blue">health care</font> costs, including <font color="blue"><font color="blue">prescription</font> drug costs</font>, are     underway at the federal and state <font color="blue">government</font> levels</td>
    </tr>
    <tr>
      <td><font color="blue">Congress </font>considers     proposals to reform the US <font color="blue"><font color="blue">health care</font> system on</font> an on-going basis</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>proposals may increase <font color="blue">government</font>al involvement in <font color="blue">health care</font> <font color="blue">and PBM </font>    services and <font color="blue">may otherwise</font> change the way our clients do business</td>
    </tr>
    <tr>
      <td>Our     clients  and  <font color="blue">prospective clients may react</font> to these proposals and the     <font color="blue">uncertainty surrounding them by cutting back</font> or delaying the purchase of our     PBM services, and <font color="blue">manufacturers</font> may react by reducing rebates or reducing     supplies of <font color="blue">certain products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">proposals could lead</font> to a decreased     demand for our services or to reduced rebates from <font color="blue">manufacturers</font></td>
    </tr>
    <tr>
      <td>In addition, both <font color="blue">Congress </font>and state <font color="blue">legislatures</font> are expected to consider     <font color="blue">legislation</font> to increase <font color="blue">government</font>al regulation of <font color="blue">managed care</font> plans</td>
    </tr>
    <tr>
      <td><font color="blue">Some     </font>of these <font color="blue">initiatives</font> would, among other things, require that health plan     <font color="blue">participants</font> have greater access to drugs not included on a plan’s formulary     and give health plan <font color="blue">participants</font> the right to sue their health plans for     malpractice when they have been denied care</td>
    </tr>
    <tr>
      <td>The scope of the <font color="blue">managed care</font>     <font color="blue">reform proposals under consideration by</font> <font color="blue">Congress </font>and state <font color="blue">legislatures</font> and     enacted by states to date vary greatly, and we <font color="blue">cannot predict</font> the extent of     future <font color="blue">legislation</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">initiatives</font> could greatly limit our     business practices and impair our ability to serve our clients</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  develop  <font color="blue">new products</font>, services and delivery channels may     <font color="blue"><font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>We operate in a highly <font color="blue">competitive</font> <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>We develop <font color="blue">new products</font> and     <font color="blue">services from</font> time to time to assist our clients in managing their pharmacy     benefit</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in developing <font color="blue">innovative products</font> and     services, our ability to attract <font color="blue">new clients</font> and retain <font color="blue"><font color="blue">existing clients</font> may</font>     suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Technology </font>is also an important component of our business, as we continue to     <font color="blue">utilize new</font> and better channels, such as the Internet, to communicate and     interact  with our clients, <font color="blue">participants</font> and business partners</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">competitors</font> are more <font color="blue">successful than us</font> in employing this <font color="blue">technology</font>, our     ability  to  attract  <font color="blue">new clients</font>, retain <font color="blue">existing clients</font> and operate     <font color="blue">efficiently may suffer</font></td>
    </tr>
    <tr>
      <td>34     ______________________________________________________________________    [61]Table of Contents       Our leverage and <font color="blue">debt service <font color="blue">obligations</font> could impede</font> our <font color="blue">operations</font> and     <font color="blue">flexibility</font></td>
    </tr>
    <tr>
      <td>In  January  2005,  we negotiated a dlra65 million credit <font color="blue">facility</font> with a     syndicate of <font color="blue">commercial banks led by</font> JPMorgan Chase Bank, NA (“JPMorgan     credit <font color="blue">facility</font>”)</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, we had <font color="blue">no outstanding borrowings</font>     under the JPMorgan credit <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>If and when we borrow funds under the     JPMorgan credit <font color="blue">facility</font>, we <font color="blue">could incur</font> substantial <font color="blue">interest expense</font> and     <font color="blue">future repayment <font color="blue">obligations</font></font></td>
    </tr>
    <tr>
      <td>Our level of debt and the limitations <font color="blue">imposed on</font> us by our debt <font color="blue">agreements</font>     could have <font color="blue">important consequences</font>, including the following:           •   we will have to use a portion of our cash flow from <font color="blue">operations</font> for     <font color="blue">debt service rather than</font> for our <font color="blue">operations</font>;           •   we may from time to time incur <font color="blue">additional</font> indebtedness under our     JPMorgan credit <font color="blue">facility</font>, which is subject to a <font color="blue">variable interest rate</font>,     making us vulnerable to increases in <font color="blue">interest rates</font>;           •   we could be less able to take advantage of <font color="blue">significant</font> business     opportunities, such as <font color="blue">acquisition</font> opportunities, and react to changes in     market or industry <font color="blue">conditions</font>;           •   we could be more vulnerable to <font color="blue">general adverse economic</font> and industry     <font color="blue">conditions</font>; and           •   we may be <font color="blue">disadvantaged compared</font> to <font color="blue">competitors</font> with less leverage</td>
    </tr>
    <tr>
      <td>Furthermore, our ability to satisfy our <font color="blue">obligations</font>, including our debt     service <font color="blue">requirements</font>, will be <font color="blue">dependent</font> upon our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Factors     </font>which could affect our <font color="blue">future performance</font> include, <font color="blue">without limitation</font>,     prevailing economic <font color="blue">conditions</font> and financial, business and other factors,     many  of  which are beyond our control and <font color="blue">which affect</font> our results of     <font color="blue">operations</font>, financial position and/or cash flow from <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our JPMorgan </font>credit <font color="blue">facility</font> is <font color="blue">secured by</font> our assets</td>
    </tr>
    <tr>
      <td>If we are unable to     meet our <font color="blue">obligations</font> under the JPMorgan credit <font color="blue">facility</font>, these <font color="blue">creditors</font>     <font color="blue">could exercise</font> their <font color="blue">rights as secured parties</font> and take possession of our     assets</td>
    </tr>
    <tr>
      <td>This would materially <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font> and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Risks related to <font color="blue">bioterrorism</font> and mail tampering, and <font color="blue">mail <font color="blue">irradiation</font></font> and     other procedures the <font color="blue">government</font> may implement to manage these risks, could     <font color="blue"><font color="blue">adversely</font> affect</font> and limit the growth of our mail and <font color="blue">specialty service</font>     business</td>
    </tr>
    <tr>
      <td>Many <font color="blue">prescription</font> drugs are delivered directly to our <font color="blue">consumers through</font> the     mail</td>
    </tr>
    <tr>
      <td>In  particular,  our mail and <font color="blue"><font color="blue">specialty service</font> pharmacies</font> send     thousands  of  parcels a <font color="blue">week through</font> the United States Postal Service     (“USPS”) and other couriers</td>
    </tr>
    <tr>
      <td>A number of our <font color="blue">contracts also</font> require us to     deliver  <font color="blue">prescription</font>s  within  a <font color="blue">designated period</font> of time on average     <font color="blue">following receipt</font> of an order</td>
    </tr>
    <tr>
      <td>We have no control, however, over delays     caused by <font color="blue">disruption</font>s to the USPS or other <font color="blue">courier services</font></td>
    </tr>
    <tr>
      <td>Moreover,     should the risks related to <font color="blue">bioterrorism</font> or mail tampering increase or Mail     Service  experience  <font color="blue">interruption</font>s  or <font color="blue">significant</font> delays, we may have     <font color="blue">difficult</font>y satisfying our contractual performance <font color="blue">obligations</font> and consumers     <font color="blue">may lose confidence</font> in our mail and <font color="blue"><font color="blue">specialty service</font> pharmacies</font></td>
    </tr>
    <tr>
      <td>Additionally, the use of <font color="blue">mail <font color="blue">irradiation</font></font> devices, if implemented, could be     harmful to <font color="blue">pharmaceutical</font> products shipped via the mail</td>
    </tr>
    <tr>
      <td>We understand that     this <font color="blue">technology</font> is not in <font color="blue">general use</font> and the USPS has not announced plans     to use <font color="blue">irradiation</font> screening on <font color="blue">prescription</font> medicines</td>
    </tr>
    <tr>
      <td>However, should the     <font color="blue">federal <font color="blue">government</font></font> implement <font color="blue">mail <font color="blue">irradiation</font></font> <font color="blue">technology</font> to <font color="blue">protect national</font>     security  due  to  the risks of <font color="blue">bioterrorism</font> via the mail or for other     unforeseen reasons, safe and <font color="blue">reliable delivery</font> of <font color="blue">prescription</font> drugs through     the mail may be <font color="blue">difficult</font></td>
    </tr>
    <tr>
      <td>If any of these events occur, we could be forced     to <font color="blue">temporarily</font> or permanently <font color="blue">discontinue</font> our mail and <font color="blue">specialty service</font>     <font color="blue">operations</font> and we would lose an important <font color="blue">competitive</font> advantage</td>
    </tr>
    <tr>
      <td>35     ______________________________________________________________________    [62]Table of Contents       Any <font color="blue">disruption</font> of or failure in our automated <font color="blue">mail service</font> pharmacy or our     data center could <font color="blue"><font color="blue">significant</font>ly</font> reduce our ability to process and dispense     <font color="blue">prescription</font>s and <font color="blue">provide products</font> and services to our clients</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">automated pharmacy</font> and <font color="blue">Mail Service </font><font color="blue">delivery system</font> is located in     Miramar, Florida</td>
    </tr>
    <tr>
      <td>Our main data center, located in Port Washington, New     York, <font color="blue">provides primary support</font> for all <font color="blue">applications</font> and systems required for     our  business <font color="blue">operations</font>, including our claims processing, billing and     <font color="blue">communications</font></td>
    </tr>
    <tr>
      <td>These facilities <font color="blue">depend on</font> the <font color="blue">infrastructure</font> in the areas     where  they  are  located  and  on  the <font color="blue">uninterrupted operation</font> of our     <font color="blue">computerized dispensing systems</font> and our <font color="blue">electronic data processing systems</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">disruption</font>s at any of these <font color="blue">facilities due</font> to failure of our     <font color="blue">technology</font> or any other failure or <font color="blue">disruption</font> to these systems or to the     <font color="blue">infrastructure</font> due to fire, electrical outage, natural disaster, acts of     terrorism or some other <font color="blue">catastrophic event could reduce</font> our ability to     process and dispense <font color="blue">prescription</font>s and <font color="blue">provide products</font> and services to our     clients</td>
    </tr>
    <tr>
      <td>Although we maintain <font color="blue">redundancies</font> and other <font color="blue">preventative measures</font>     to protect against <font color="blue">disruption</font> of these systems, there can be no assurance     that <font color="blue">redundant systems will</font> in fact operate as intended or with the same     effect as the <font color="blue">primary systems</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">withdrawal from</font> the market and <font color="blue"><font color="blue">utilization</font> <font color="blue">decreases</font> based off</font> of     <font color="blue">increased safety risk profiles</font> of <font color="blue">specific drugs may</font> cause <font color="blue">prescription</font>     volumes to decline and our <font color="blue">net revenues</font> and <font color="blue">profitability</font> may be <font color="blue">negatively</font>     impacted</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net revenues</font> and <font color="blue">profitability</font> are <font color="blue">based on</font> the dispensing of brand-name     and <font color="blue">generic drugs</font> by our <font color="blue">Mail Service </font>and Specialty Service pharmacies and     <font color="blue">retail pharmacies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Withdrawal </font>of these products by the <font color="blue">manufacturers</font> or     <font color="blue">utilization</font>  <font color="blue">decreases</font>  based off of <font color="blue">increased safety risk profiles</font> of     specific drugs or classes of drugs may cause physicians to cease writing or     reduce the numbers of <font color="blue">prescription</font>s written for these drugs</td>
    </tr>
    <tr>
      <td>In  these cases, if there are no acceptable     <font color="blue">prescription</font> drug equivalents or <font color="blue">alternatives</font> for these <font color="blue">prescription</font> drugs,     our volumes, <font color="blue">net revenues</font>, <font color="blue">profitability</font> and <font color="blue">cash flows may decline</font></td>
    </tr>
    <tr>
      <td>The launch of generic <font color="blue">pharmaceutical</font>s into the <font color="blue">marketplace may impact</font> our     financial results</td>
    </tr>
    <tr>
      <td>A great deal of our earned rebates on drugs comes from drugs whose patents     will expire over the <font color="blue">next several years</font></td>
    </tr>
    <tr>
      <td>When these patents expire, generic     <font color="blue">products will</font> be introduced and may <font color="blue">substantially</font> reduce the market share of     brand-<font color="blue">name drugs</font> and the rebates <font color="blue">manufacturers</font> provide to us for their     brand-<font color="blue">name drugs</font> that are included on the <font color="blue">formularies</font> we manage</td>
    </tr>
    <tr>
      <td>We may also     be unable to <font color="blue">negotiate rebates</font> for new brand-<font color="blue">name drugs</font> comparable to the     rebates we are receiving from brand-<font color="blue">name drugs</font> with expiring patents</td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font>though we generally earn <font color="blue">higher margins</font> on <font color="blue">generic drugs</font> than we earn on     brand-<font color="blue">name drugs</font>, <font color="blue">manufacturers</font> of newly-introduced <font color="blue">generic drugs</font> sometimes     benefit from an exclusive marketing period, generally six months, during     which time we may be unable to earn these <font color="blue">higher margins</font></td>
    </tr>
    <tr>
      <td>Therefore, the     typically  higher  margins  we  earn on <font color="blue">generic drugs</font> and rebates from     newly-approved, brand-<font color="blue">name drugs</font> may not offset any decline in rebates for     brand-<font color="blue">name drugs</font> with expired patents</td>
    </tr>
  </tbody>
</table>